Literature DB >> 27057672

Synergistic effects of resveratrol (free and inclusion complex) and sulfamethoxazole-trimetropim treatment on pathology, oxidant/antioxidant status and behavior of mice infected with Toxoplasma gondii.

Nathieli B Bottari1, Matheus D Baldissera2, Alexandre A Tonin3, Virginia C Rech2, Catiane B Alves2, Fernanda D'Avila2, Gustavo R Thomé1, Naiara S Guarda4, Rafael N Moresco4, Giovana Camillo5, Fernanda F Vogel5, Cristiane Luchese6, Maria Rosa C Schetinger1, Vera M Morsch1, Camila Tochetto7, Rafael Fighera7, Vivian S K Nishihira2, Aleksandro S Da Silva8.   

Abstract

This study aimed to investigate the synergistic effects of resveratrol and sulfamethoxazole-trimethoprim (ST) on the treatment of mice experimentally infected by Toxoplasma gondii during the chronic phase of the disease considering infection, behavior, and oxidative/antioxidants profile aspects. For the study, 60 mice were initially divided into two groups: uninfected (n = 24) and infected by T. gondii (n = 36). These two groups were later subdivided into other groups and treated with resveratrol (free and inclusion complex containing resveratrol) alone and co-administered with ST: groups A to D were composed by healthy mice and groups E to J were consisted of animals infected by T. gondii (VEG strain). Treatments began 20 days post-infection for 10 consecutive days with oral doses of 0.5 mg kg(-1) of ST (groups B and F), 100 mg kg(-1) of free resveratrol (groups C and G) and inclusion complex of resveratrol (nanoparticles containing resveratrol) (groups D and H), and lastly an co-administration of both drugs (groups I and J). Behavioral tests (memory, anxiety and locomotion) were performed after treatment. Liver and brain fragments were collected to evaluate pathological changes, brain cysts counts, as well as oxidant and antioxidant levels. A reduction on the number of cysts in the brain of animals treated with both drugs combined was observed; there was also reduced number of lesions on both organs. This drug combined effect was also able to reduce oxidative and increase antioxidant levels in infected mice, which might be interpreted as a resveratrol protective effect. In addition, the combination of ST and resveratrol was able to prevent behavioral changes in infected mice. Therefore, the use of co-administration drugs enhances the therapeutic effect acting on a synergic way, reducing the oxidizing effects of the chemical treatment for toxoplasmosis. In addition, resveratrol in inclusion complex when co-administered with ST showed an improved therapeutic effect of ST reducing oxidative damage, liver damage and the number of cysts in the brain of T. gondii infected mice.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Behavior; Nanotecnology; Oxidants/antioxidants; Resveratrol; Toxoplasma gondii

Mesh:

Substances:

Year:  2016        PMID: 27057672     DOI: 10.1016/j.micpath.2016.04.002

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  11 in total

Review 1.  Nanomedicine advances in toxoplasmosis: diagnostic, treatment, and vaccine applications.

Authors:  João Paulo Assolini; Virginia Márcia Concato; Manoela Daiele Gonçalves; Amanda Cristina Machado Carloto; Ivete Conchon-Costa; Wander Rogério Pavanelli; Francine Nesello Melanda; Idessania Nazareth Costa
Journal:  Parasitol Res       Date:  2017-05-05       Impact factor: 2.289

2.  Toxoplasma gondii Infection in Mice Impairs Long-Term Fear Memory Consolidation through Dysfunction of the Cortex and Amygdala.

Authors:  Fumiaki Ihara; Maki Nishimura; Yoshikage Muroi; Motamed Elsayed Mahmoud; Naoaki Yokoyama; Kisaburo Nagamune; Yoshifumi Nishikawa
Journal:  Infect Immun       Date:  2016-09-19       Impact factor: 3.441

Review 3.  Activities of anti-Toxoplasma drugs and compounds against tissue cysts in the last three decades (1987 to 2017), a systematic review.

Authors:  Mahbobeh Montazeri; Saeed Mehrzadi; Mehdi Sharif; Shahabeddin Sarvi; Shayesteh Shahdin; Ahmad Daryani
Journal:  Parasitol Res       Date:  2018-08-08       Impact factor: 2.289

Review 4.  Impact of Plant-Based Foods and Nutraceuticals on Toxoplasma gondii Cysts: Nutritional Therapy as a Viable Approach for Managing Chronic Brain Toxoplasmosis.

Authors:  Sijie Tan; Wen Han Tong; Ajai Vyas
Journal:  Front Nutr       Date:  2022-02-25

5.  Effective inhibition of MERS-CoV infection by resveratrol.

Authors:  Shih-Chao Lin; Chi-Tang Ho; Wen-Ho Chuo; Shiming Li; Tony T Wang; Chi-Chen Lin
Journal:  BMC Infect Dis       Date:  2017-02-13       Impact factor: 3.090

Review 6.  A Systematic Review of In vitro and In vivo Activities of Anti-Toxoplasma Drugs and Compounds (2006-2016).

Authors:  Mahbobeh Montazeri; Mehdi Sharif; Shahabeddin Sarvi; Saeed Mehrzadi; Ehsan Ahmadpour; Ahmad Daryani
Journal:  Front Microbiol       Date:  2017-01-20       Impact factor: 5.640

7.  Therapeutic potential of a novel combination of Curcumin with Sulfamethoxazole against carbon tetrachloride-induced acute liver injury in Swiss albino mice.

Authors:  Rasha Fekry Zahran; Zeinab M Geba; Ashraf A Tabll; Mohammad M Mashaly
Journal:  J Genet Eng Biotechnol       Date:  2020-05-04

8.  Rosuvastatin revert memory impairment and anxiogenic-like effect in mice infected with the chronic ME-49 strain of Toxoplasma gondii.

Authors:  Fernanda Ferreira Evangelista; Willian Costa-Ferreira; Francini Martini Mantelo; Lucimara Fátima Beletini; Amanda Hinobu de Souza; Priscilla de Laet Sant'Ana; Keller Karla de Lima; Carlos Cesar Crestani; Ana Lúcia Falavigna-Guilherme
Journal:  PLoS One       Date:  2021-04-15       Impact factor: 3.240

Review 9.  Oxidative Stress as a Possible Target in the Treatment of Toxoplasmosis: Perspectives and Ambiguities.

Authors:  Karolina Szewczyk-Golec; Marta Pawłowska; Roland Wesołowski; Marcin Wróblewski; Celestyna Mila-Kierzenkowska
Journal:  Int J Mol Sci       Date:  2021-05-27       Impact factor: 5.923

10.  In Vitro Screening to Identify Anti-Toxoplasma Compounds and In Silico Modeling for Bioactivities and Toxicity.

Authors:  Oluyomi Stephen Adeyemi; Olubunmi Atolani; Oluwakemi Josephine Awakan; Tomilola Debby Olaolu; Charles Obiora Nwonuma; Omokolade Alejolowo; David Adeiza Otohinoyi; Damilare Rotimi; Akinyomade Owolabi; Gaber El-Saber Batiha
Journal:  Yale J Biol Med       Date:  2019-09-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.